2022年
- November 9, 2022
- Summary of Consolidated Financial Results(For the second quarter ended September 30, 2022) [Japanese Standard]
- November 9, 2022
- Second Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2023 (Nov 9, 2022) - Supplementary Information
- November 9, 2022
- KYORIN and SUSMED conclude Collaboration Research and Sales Agreement for development of DTx in Otolaryngology Field
- August 2, 2022
- Summary of Consolidated Financial Results(For the first quarter ended June 30, 2022) [Japanese Standard]
- August 2, 2022
- First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2023 (Aug 2, 2022) - Supplementary Information
- August 2, 2022
- Notice Regarding Decision on Termination and Dissolution of Business in Consolidated Subsidiaries, ActivX Biosciences, Inc.
- June 17, 2022
- KYORIN Signs Joint Development and License Agreement for Genetically modified Adipocyte, Treatment Agent for Fabry Disease
- May 11, 2022
- Summary of Consolidated Financial Results(For the fiscal year ended March 31, 2022) [Japanese Standard]
- May 11, 2022
- Consolidated Financial Results for the Fiscal Year Ended March 31, 2022 (May 11, 2022) - Supplementary Information
- May 11, 2022
- Notice of Reduction of Capital Reserve
- April 20, 2022
- NHI Drug Price Listing and Release of a selective P2X3 receptor antagonist for the treatment of cough "Lyfnua® Tablet 45 mg"
- February 24, 2022
- Construction of the Takaoka New Plant by a Subsidiary Company
- February 4, 2022
- Summary of Consolidated Financial Results (For the Third Quarter Ended December 31, 2021) [Japanese Standard]
- February 4, 2022
- Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2022 - Supplementary Information
- 1